论文部分内容阅读
克罗米芬与人绝经期促性腺激素(hMG)可使患多囊卵巢症妇女的生殖能力有所改进。克罗米芬现在最常用于治疗此症,但约有30%患者无反应。尽管对于克罗米芬治疗无效者可用hMG与hCG来诱导排卵,但可使患者发生卵巢过度刺激征,增加多胎妊娠率及早期流产率。已知,多囊卵巢症患者无排卵可能与雄激素水平升高有关。作者曾证明用地塞米松抑制雄激素可以提高排卵率和妊娠率。本文观察了一组用hMG-hCG治疗未妊娠的多囊卵巢症患者,以期阐明用低剂量地塞米松降低雄激素水平是否能改进患者对hMG-hCG治疗的反应性。 27例诊断为多囊卵巢症的不育妇女,曾用hM
Clomiphene and human menopausal gonadotrophin (hMG) may improve fertility in women with polycystic ovary. Clomiphene is now most commonly used to treat this condition, but about 30% of the patients do not respond. Although hMG and hCG can be used to induce ovulation in patients who are refractory to clomiphene, ovulation hyperstimulation can be used to increase multiple pregnancy rates and early miscarriage rates. It is known that anovulatory patients with polycystic ovary may be related to elevated androgen levels. The authors have shown that inhibition of androgens with dexamethasone can improve ovulation and pregnancy rates. This article looked at a group of hCG-hCG-treated women with polycystic ovary, in an attempt to elucidate whether lowering the level of androgens with low-dose dexamethasone improves the responsiveness of patients to hMG-hCG therapy. Twenty-seven infertile women diagnosed with polycystic ovary were treated with hM